Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients

Mudd, 1995, Disorders of transsulfuration, 1279 Selhub, 1992, The pathogenesis of homocysteinemia: Interuption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine, Am J Clin Nutr, 55, 131, 10.1093/ajcn/55.1.131 Kang, 1992, Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease, Annu Rev Nutr, 12, 279, 10.1146/annurev.nu.12.070192.001431 Clarke, 1991, Hyperhomocysteinemia: An independent risk factor for vascular disease, N Engl J Med, 324, 1149, 10.1056/NEJM199104253241701 Malinow, 1996, Plasma homocyst(e)ine: A risk factor for arterial occlusive diseases, J Nutr, 126, 1238S, 10.1093/jn/126.suppl_4.1238S den Heijer, 1996, Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Engl J Med, 334, 759, 10.1056/NEJM199603213341203 Wilcken, 1980, Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenaince haemodialysis, Clin Sci, 58, 427, 10.1042/cs0580427 Kang, 1983, Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis, Clin Sci, 65, 335, 10.1042/cs0650335 Smolin, 1987, Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis, Am J Clin Nutr, 45, 737, 10.1093/ajcn/45.4.737 Hultberg, 1993, Plasma homocysteine in renal failure, Clin Nephrol, 40, 230 Chauveau, 1993, Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients, Kidney Int, 43, S72 Arnadottir, 1993, The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients, Clin Nephrol, 40, 236 Bachmann, 1995, Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients, J Am Soc Nephrol, 6, 121, 10.1681/ASN.V61121 Bostom, 1995, Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study, Atherosclerosis, 114, 93, 10.1016/0021-9150(94)05470-4 Friedman, 1995, Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis, Nutr Rev, 53, 197, 10.1111/j.1753-4887.1995.tb01551.x Robinson, 1996, Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations, Circulation, 94, 2743, 10.1161/01.CIR.94.11.2743 Harker, 1974, Homocystinemia: Vascular injury and arterial thrombosis, N Engl J Med, 291, 537, 10.1056/NEJM197409122911101 Harker, 1976, Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis, J Clin Invest, 58, 731, 10.1172/JCI108520 Starkebaum, 1986, Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine, J Clin Invest, 77, 1370, 10.1172/JCI112442 Stamler, 1993, Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen, J Clin Invest, 91, 308, 10.1172/JCI116187 Upchurch, 1996, Homocysteine, EDRF and endothelial function, J Nutr, 126, 1290S, 10.1093/jn/126.suppl_4.1290S Wilcken, 1989, Mechanisms of thrombogenesis and accelerated atherogenesis in homocysteinaemia, Haemostasis, 19, 14 Harpel, 1996, Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis, 1285S Tsai, 1996, Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells, J Clin Invest, 97, 146, 10.1172/JCI118383 Heinecke, 1987, The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells, J Biol Chem, 262, 10098, 10.1016/S0021-9258(18)61082-8 Mudd, 1972, Homocystinuria associated with decreased methylenetetrahydro-folate reductase activity, Biochem Biophys Res Commun, 46, 905, 10.1016/S0006-291X(72)80227-4 Kang, 1988, Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase, Am J Hum Genet, 43, 414 Brattström, 1988, Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency, Metabolism, 37, 175, 10.1016/S0026-0495(98)90014-2 Robinson, 1995, Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease, Circulation, 92, 2825, 10.1161/01.CIR.92.10.2825 Kang, 1987, Homocysteinemia due to folate deficiency, Metabolism, 36, 458, 10.1016/0026-0495(87)90043-6 Brattström, 1996, Vitamins as homocysteine-lowering agents, J Nutr, 126, 1276S, 10.1093/jn/126.suppl_4.1276S Frosst, 1995, A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase, Nat Genet, 10, 111, 10.1038/ng0595-111 Araki, 1987, Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection, J Chromatogr, 422, 43, 10.1016/0378-4347(87)80438-3 Bostom, 1996, Folate status, a common mutation in the methylene-tetrahydrofolate reductase, and fasting total plasma homocysteine levels in dialysis patients, J Am Soc Nephrol, 7, 1474 Motulsky, 1996, Nutritional ecogenetics: Homocysteine-related arte-riosclerotic vascular disease, neural tube defects, and folic acid, Am J Hum Genet, 58, 17 Ma, 1996, Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians, Circulation, 94, 2410, 10.1161/01.CIR.94.10.2410 Kluijtmans, 1996, Molecular genetic analysis in mild hyperhomocysteine mia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease, Am J Hum Genet, 58, 35 Kang, 1988, Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease, Metabolism, 37, 611, 10.1016/0026-0495(88)90076-5 Engbersen, 1995, Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia, Am J Hum Genet, 56, 142 de Franchis, 1996, Elevated total plasma homocysteine and 677C - T mutation of the 5,10-methylenetrahydrofolate reductase gene in thrombotic vascular disease, Am J Hum Genet, 59, 262 Gallagher, 1996, Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation, Circulation, 94, 2154, 10.1161/01.CIR.94.9.2154 Lindner, 1974, Accelerated atherosclerosis in prolonged maintainance hemodialysis, N Engl J Med, 290, 697, 10.1056/NEJM197403282901301 Ma, 1992, Cardiovascular risk factors in chronic renal failure and hemodialysis populations, Am J Kidney Dis, 19, 505, 10.1016/S0272-6386(12)80827-4 Degoulet, 1982, Mortality risk factors in patients treated by chronic hemodialysis, Nephron, 31, 103, 10.1159/000182627 Parfey, 1994, Long-term cardiac morbidity and mortality during dialysis therapy, Adv Nephrol, 23, 311 Churchill, 1990, Results of the Canadian morbidity study in end-stage renal disease patients treated by hemodialysis, Semin Nephrol, 10, 66 Bostom, 1996, High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients, Kidney Int, 49, 147, 10.1038/ki.1996.19 Wilcken, 1979, Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide, EurJ Clin Invest, 9, 301, 10.1111/j.1365-2362.1979.tb00888.x Ceballos, 1990, Early alterations of plasma free amino acids in chronic renal failure, Clin Chim Acta, 188, 101, 10.1016/0009-8981(90)90154-K Soria, 1990, Concentrations of total homocysteine in plasma in chronic renal failure, Clin Chem, 36, 2137, 10.1093/clinchem/36.12.2137 Kang, 1979, Protein-bound homocyst(e)ine in normal subjects and in patients with homocystinuria, Pediatr Res, 13, 1141, 10.1203/00006450-197910000-00012 Refsum, 1985, Radioenzymic determination of homocysteine in plasma and urine, Clin Chem, 31, 624, 10.1093/clinchem/31.4.624 Foreman, 1982, Homocystine uptake in isolated rat renal cortical tubules, Metabolism, 31, 613, 10.1016/0026-0495(82)90101-9 McKeever, 1991, Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat, Clin Sci, 81, 551, 10.1042/cs0810551 Gaull, 1973, Development of methyltransferase activities of human fetal tissues, Pediat Res, 7, 527, 10.1203/00006450-197305000-00006 Hultberg, 1991, Increased levels of plasma homocys teine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus, Scand J Clin Lab Invest, 51, 277, 10.3109/00365519109091615 Perna, 1995, Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia, Kidney Int, 47, 247, 10.1038/ki.1995.31 Bostom, 1996, Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients, Atherosclerosis, 123, 193, 10.1016/0021-9150(96)05809-1 Rozen, 1995, Interaction of a common mutation in methylenetet rahydrofolate reductase (MTHFR) with low folate status in hyperhomocysteinemia, Am J Hum Genet, 57, A250 Jacques, 1996, Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations, Circulation, 93, 7, 10.1161/01.CIR.93.1.7 Brattström, 1988, Folic acid—An innocuous means to reduce plasma homocysteine, Scand J Clin Lab Invest, 48, 215, 10.3109/00365518809167487 Wilcken, 1988, Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease, Me tabolism, 37, 697 Kang, 1996, Treatment of hyperhomocyst(e)inemia: Physiological basis, J Nutr, 126, 1273S, 10.1093/jn/126.suppl_4.1273S